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Abstract
GPR105, a G-protein coupled receptor for UDP-glucose, is highly expressed in several human
tissues and participates in the innate immune response. Since inflammation has been implicated as
a key initial trigger for type 2 diabetes, we hypothesized that GPR105 (official gene name:
P2RY14) might play a role in the initiation of inflammation and insulin resistance in obesity. To
this end, we investigated glucose metabolism in GPR105 knockout (KO) and wild-type (WT)
mice fed a high-fat diet (HFD). We also examined whether GPR105 regulates macrophage
recruitment to liver or adipose tissues by in vivo monocyte tracking and in vitro chemotaxis
experiments, followed by transplantation of bone marrow from either KO or WT donors to WT
recipients. Our data show that genetic deletion of GPR105 confers protection against HFD-
induced insulin resistance, with reduced macrophage infiltration and inflammation in liver, and
increased insulin-stimulated Akt phosphorylation in liver, muscle and adipose tissue. By tracking
monocytes from either KO or WT donors, we found that fewer KO monocytes were recruited to
the liver of WT recipients. Furthermore, we observed that UDP-Glc enhanced the in vitro
migration of bone marrow-derived macrophages from WT but not KO mice, and that plasma
UDP-Glc levels were significantly higher in obese versus lean mice. Finally, we confirmed that
insulin sensitivity improved in HFD mice with a myeloid cell-specific deletion of GPR105. These
studies indicate that GPR105 ablation mitigates HFD-induced insulin resistance by inhibiting
macrophage recruitment and tissue inflammation. Hence, GPR105 provides a novel link between
innate immunity and metabolism.
INTRODUCTION
Insulin resistance is a major metabolic feature of obesity and a key factor in the pathogenesis
of type 2 diabetes. Many lines of evidence show that the activation of proinflammatory
pathways within insulin target tissues can impair insulin signaling, and chronic, low-level
tissue inflammation is now recognized as an important cause of systemic insulin resistance
(1). Several studies have shown that macrophages, a key component of the innate immune
defense against pathogens, are critical effector cells in this proinflammatory process.
Macrophages present in non-inflamed tissues (resident macrophages) help maintain
homeostasis and participate in tissue remodeling (2). However, in obese states, macrophages
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accumulate in fat, liver and muscle tissues, secreting proinflammatory cytokines such as
TNF-α and IL-6 that induce cellular insulin resistance by the activation of JNK or IκB
kinase β signaling with serine phosphorylation of insulin receptor substrate proteins.
Macrophages that are newly recruited following high-fat diet exposure have been shown to
differ from resident macrophages in adipose tissue, showing increased proinflammatory
properties (3). Although both innate and adaptive immune systems have been implicated in
macrophage activation and recruitment in obesity (4), the precise mechanisms that regulate
the recruitment of new macrophages to insulin target tissues are unclear.
G-protein coupled receptors (GPCRs) mediate a variety of physiological functions, which
poise these proteins as therapeutic targets in metabolic disease. They are also the target of
approximately half of all modern medicinal drugs (5). GPR105 (also known as the P2Y14
receptor) is a member of a GPCR subgroup potently activated by pyrimidine UDP-sugars,
especially uridine 5-diphosphoglucose (UDP-Glc) (6). GPR105 is broadly expressed in
several human tissues, including the placenta, adipose tissue, stomach, intestine and discrete
brain regions(6). Notably, GPR105 is also prominently expressed in immune cells, including
macrophages, lymphocytes and neutrophils (7–9). Previous studies have revealed that
GPR105 regulates leukocyte chemotaxis in response to UDP-Glc (10, 11).
Since, GPR105 participates in the innate immune response, we hypothesized that GPR105
may contribute to the initiation of obesity-induced insulin resistance. Here we have assessed
the effects of whole body and bone marrow-specific deletion of GPR105 (official gene
name: P2ry14) on insulin action and glucose homeostasis. We show that GPR105 in
immune cells mediates macrophage recruitment to the liver in chronic HFD feeding with
subsequent local inflammation and insulin resistance. Thus GPR105 may provide a novel
link between innate immunity and insulin resistance.
MATERIALS AND METHODS
Animals
GPR105 (P2ry14) null mice were purchased from Taconic and have been previously
described (12). Briefly, embryonic stem cells from 129P2 mice were manipulated by
replacement of the P2ry14 gene open reading frame by a LacZ-neo cassette and
subsequently injected into C57BL/6J blastocytes to generate GPR105 KO mice. In our
animal facility, these mice were back-crossed to C57Bl/6N mice obtained from Harlan
Laboratories for 6 generations. Heterozygous mice from the 7th generation were then used to
breed WT and GPR105 KO littermates used for all experiments described here. Mice were
fed either a normal chow (NC) or HFD (60% kcal from fat; D12492, Research Diets), and
maintained on a 12h light/dark cycle with free access to food and water. For bone marrow
transplantation studies, 10w C57BL/6N mice (Harlan, California) were exposed to 10-Gy of
Co-60 irradiation and injected with bone marrow cells from WT or GPR105 KO mice within
24h. Eight weeks after transplantation, mice were fed either NC or HFD for 12w to generate
lean or obese/insulin resistant phenotypes. All mouse procedures conformed to the Guide for
Care and Use of Laboratory Animals of the US National Institutes of Health and were
approved by the Animal Subjects Committee of the University of California, San Diego.
Metabolic studies
Glucose and insulin tolerance tests (GTT and ITT, respectively) were performed on 7h
fasted mice. Animals were given intraperitoneal or oral dextrose (1 g/kg, Hospira, Inc.) for
the GTT, or intraperitoneal insulin (0.6 U/kg, Novolin R, Novo-Nordisk) for the ITT.
Glucose levels after injection were monitored over time. Blood samples were drawn by tail
nick at basal and indicated times, and glucose was measured using a One-Touch glucose
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meter (Lifescan). Hyperinsulinemic-euglycemic clamp studies were performed as previously
described (13, 14). In brief, two jugular catheters were inserted under anesthesia, tunneled to
the mid-scapular region and externalized. Five days later, the clamp experiments began with
the infusion of an equilibration solution of D-[3-3H] glucose (NEN, Boston) for 90 min at a
constant rate of 5 μCi/h. Then, insulin was infused at 8 mU/kg/min while the glucose
infusion rate was adjusted as necessary until euglycemia was achieved (~120 mg/dl for >20
min). Blood samples were collected prior to insulin infusion and upon euglycemia to
confirm steady-state. At steady-state, the rate of glucose disappearance (total glucose
disposal rate or GDR) equals the sum of hepatic glucose production (HGP) and the glucose
infusion rate (GIR). The insulin-stimulated GDR (IS-GDR) is equal to the total GDR minus
the basal glucose turnover rate. Serum insulin levels were analyzed by ELISA (Alpco
Diagnostics).
Triglyceride and glycogen measurements
Triglyceride (TG) content was measured in liver homogenates in PBS containing 5% Triton
X-100 and in plasma samples (EnzyChrom™, BioAssay Systems, Hayward, CA). Glycogen
levels were measured by the method of Seifter et al. (15).
Histology
H&E staining in liver and adipose tissue sections was conducted by the University of
California, San Diego histology core at the Moore’s Cancer Center. Anti-Mac2 (Cedarlane
Labs) and Anti-F4/80 (Abcam, MA) antibodies were used for immunohistochemistry.
Immunoblot analysis
For insulin-stimulated phospho-Akt analysis, mice were fasted for 7h and then injected with
0.2 U/kg insulin via the inferior vena cava under anesthesia. Tissues were taken before or
after injection (3 min for liver and 10 min for epididymal white adipose tissue [eWAT] and
skeletal muscle), snap frozen, and subjected to western blot analyses performed according to
standard techniques. Antibodies against p-Akt (Ser473), Akt and α-tubulin were obtained
from Cell Signaling Technologies (Beverly, MA). To measure Akt phosphorylation,
solubilized extracts containing equal amounts of tissue protein were immunoblotted with
rabbit polyclonal antibodies against either Akt or phospho-Ser473 Akt (Cell Signaling
Technology, Beverly, MA), followed by second antibody detection. For quantification, the
relative intensities of protein bands were measured with ImageJ and expressed as arbitrary
units.
RNA isolation and quantitative RT-PCR
Total RNA was isolated from cells and tissues using TRIzol Reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. First strand cDNA was synthesized using
a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA).
The samples were run in 20 μl reactions using an MJ Research PTC-200 96 well
thermocycler coupled with the Chromo 4 Four-Color Real-Time System (GMI, Inc.,
Ramsey, MN). Gene expression levels were calculated after normalization to the standard
housekeeping gene RNA polymerase II (RPII) using the ΔΔCT method as described
previously (16). Primer sequences are available in supplemental Table S1.
Monocyte tracking
Blood collected from the retro-orbital sinus of WT or GPR105 KO mice was subjected to
red blood cell lysis, and monocyte subsets were enriched with the EasySep® mouse
monocytes enrichment kit (STEMCELL Technologies, Vancouver, BC). Isolated monocytes
from 10–15 mice of each genotype were pooled together. These monocytes (5×105 to
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10×105) were then washed in serum-free RPMI and suspended in 2 ml of Diluent solution C.
PKH26 (Sigma-Aldrich, St Louis, MO) dissolved at 2×10−3 M in Diluent C was added, and
the cells were incubated for 10 min at room temperature in the dark. The staining reaction
was halted by the addition of an equal volume of medium supplemented with 10% FBS. The
mixture was centrifuged, and the cells were washed once and re-suspended in serum-
containing medium. Subsequent to labeling with PKH26, the monocytes were counted and
~1×105 viable cells were suspended in 0.2 ml PBS and injected into the femoral vein of WT
mice who were receiving HFD. Five days after injection, adipose tissue macrophages
(ATMs) and liver non-parenchymal cells were isolated and analyzed by FACS analysis.
FACS analysis of macrophages from the adipose stromal vascular fraction and liver
Epididymal fat pads were weighed, rinsed in PBS, and then minced in FACS buffer (PBS/
1% BSA). Adipocytes and stromal vascular cells were prepared from collagenase-digested
adipose tissue (17). Liver macrophage cells were prepared by a two-step liver collagenase
digestion and fractionation on a density gradient (18). FACS analysis of stromal vascular
cells for macrophage content and subtypes were performed as previously described (17).
The antibodies used for surface staining were F4/80 (BM8), CD11b (M1/70) and CD11c
(N418) (eBioscience, San Diego, CA).
BMDM culture and in vitro chemotaxis assay
Bone marrow-derived macrophage (BMDM) culture was performed as previously described
(17). Briefly, bone marrow cells were flushed from the femurs and tibias of 10–12-week-old
WT and GPR105 KO mice. The cells were then differentiated into BMDMs in RPMI
medium containing recombinant M-CSF, low endotoxin FBS and streptomycin/penicillin.
Five days after differentiation, cells were harvested and suspended in DMEM with 1g/L
glucose. The in vitro chemotaxis assay was performed as previously described (19).
Approximately 105 cells were seeded into the upper chamber of an 8 μM polycarbonate
filter (24-transwell format; Corning, Lowell, MA), and DMEM with indicated
concentrations of UDP-Glc was placed in the lower chamber. After 3h, the cells that had
migrated to the lower chamber were counted.
Measurement of UDP-glucose levels in plasma
Plasma samples were deproteinized with 5% trichloroacetic acid (TCA) followed by ethyl
ether extraction and neutralization. The UDP-Glc content in the extracts was quantified
using the assay that is based on enzymatic conversion of 32P-pyrophosphate (32PPi) +
UDP-glucose into [32P]UTP + glucose-1P, as previously described(20). Briefly, samples
were incubated for 1 h in the presence of 1 U/ml UDP-Glc pyrophosphorylase from baker’s
yeast (Sigma) and 100 nM 0.1 μCi 32-PPi (Perkin Elmer). Incubations were terminated by
the addition of 0.5 mM PPi and subsequent heating (2 min at 95°C). The resulting 32P-
species were separated by HPLC, via a Nova-Pack C18 column (Waters), and quantified on-
line with a Flo-One 500TR Radiomatic analyzer (Packard). A calibration curve using known
amounts of UDP-glucose (Fluka) was performed in parallel.
Statistical Analysis
All values are expressed as means ± SEM unless otherwise noted. We used Student’s two-
tailed t-test or ANOVA to determine differences between groups, and repeated measures
ANOVA testing for comparisons over time. P values of <0.05 were considered significant.
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GPR105 deletion protects mice from high fat diet-induced insulin resistance
To investigate the functional role of GPR105 in HFD-induced obesity, 8-week-old GPR105
KO and their wild-type littermates were fed a NC or 60% HFD for 16 weeks. Whole body
weights did not differ between GPR105 KO mice and their WT controls on either diet
(Figure 1A). HFD food intake was also similar between genotypes (Figure 1B).
On the NC diet, there were no differences in glucose tolerance (Figure 1C) or fasting insulin
levels (Figure 1D) between WT and GPR105 KO mice. Following HFD-feeding, WT mice
developed severe glucose intolerance, as expected (Figure 1C). However, HFD-fed GPR105
KO mice were protected from HFD-induced defects in glucose tolerance, with significantly
lower glucose excursions during the IPGTT (Figure 1C). Despite similar basal glucose
values, fasting insulin levels were also lower in HFD GPR105 KO mice compared to WT
controls (Figure 1D and E), suggesting that the improved glucose tolerance was secondary
to reduced insulin resistance. This finding was further supported by decreased insulin values
measured 15 min following an oral dextrose challenge (Figure 1E) and a greater
hypoglycemic response during ITT (Figure 1F) in HFD-fed GPR105 KO mice. These data
indicate improved insulin sensitivity in HFD-fed obese GPR105 KO mice.
Improved insulin sensitivity in HFD-fed GPR105 KO mice
To further investigate in vivo insulin sensitivity in HFD-fed WT and GPR105 KO mice, we
performed hyperinsulinemic-euglycemic glucose clamp studies. These studies further
supported our GTT and ITT findings with a 3-fold increase in the glucose infusion rate in
GPR105 KO mice compared to controls (Figure 2A). Total glucose turnover (Figure 2B)
and insulin-stimulated glucose disposal rates (IS-GDR) (Figure 2C) were also significantly
enhanced in GPR105 KO mice. Since 70–80% of the IS-GDR is attributable to skeletal
muscle glucose uptake, these results suggest that the deletion of GPR105 leads to improved
skeletal muscle insulin sensitivity.
GPR105 KO mice also demonstrated significantly lower rates of hepatic glucose production
(HGP) under both basal and steady-state clamp conditions (Figure 2D), indicating that the
ability of insulin to suppress HGP was enhanced in HFD-fed GPR105 KO mice (Figure 2E).
Consistent with the improved hepatic and skeletal muscle insulin sensitivity found in the
clamp studies, AKT phosphorylation was significantly increased in liver, adipose and
skeletal muscle tissues of GPR105 KO mice following insulin stimulation (Figure 2F).
Taken together, these in vivo results support the conclusion that GPR105 KO mice exhibit
improved systemic insulin sensitivity following HFD with enhanced insulin action in liver,
skeletal muscle and adipose tissues.
Reduced liver steatosis and inflammation in GPR105 KO mice
Liver weights were decreased in the GPR105 KO mice (Figure 3A) despite the similar body
weights of GPR105 KO and WT mice. GPR105 KO mice also demonstrated lower liver
triglyceride and glycogen content (Figure 3B and C) as well as a lower grade of hepatic
steatosis by histology (Figure 3D).
Notably, although GPR105 KO mice exhibited improved hepatic insulin sensitivity,
GPR105 expression was much lower in hepatocytes compared to non-parenchymal cells
which include Kupffer cells, recruited macrophages, and other immune cell types (Figure
3E). Therefore, we considered that the improved metabolic phenotype in the liver could be
attributable to crosstalk between hepatocytes and these immune cell types. Interestingly,
immunohistochemistry with F4/80, a marker of tissue macrophages (21), showed reduced
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F4/80 staining in liver from HFD-fed GPR105 KO mice when compared to WT controls,
suggesting a reduced number of either Kupffer cells or recruited macrophages in the absence
of GPR105 (Figure 3F).
Flow cytometry analysis of non-parenchymal cells from HFD liver showed a significantly
lower percentage of F4/80+ cells from GPR105 KO mice (Figure 3G), consistent with
reduced liver inflammation. Furthermore, gene expression of several pro-inflammatory
cytokines (IL-1β, IL-10, IL-6 and TNF-α) was profoundly diminished in liver tissues from
GPR105 KO mice (Figure 3H). Of note, fatty acid synthetase (FAS) and ACC were
decreased, while peroxisomal proliferator-activated receptor (PPAR)α, medium-chain acyl-
CoA dehydrogenase (MCAD), PPARγ coactivator-1 (PGC1)β, mitochondrial transcription
factor A (TFAM), and subunit 2 of cytochrome c oxidase (COX2) were increased (Figure
4G), suggesting that decreased lipogenesis and increased fatty acid oxidation may both
contribute to the improved hepatic steatosis observed in GPR105 KO mice.
Adipose tissue characteristics of GPR105 KO mice
HFD-induced adipose tissue inflammation is an important initial event in the development
of insulin resistance, occurring as early as 3d following the initiation of HFD (22).
Therefore, we examined adipose tissue from HFD-fed GPR105 KO and WT mice. No
significant differences in eWAT weights were observed between genotypes (Figure 4A).
Interestingly, GPR105 expression was detected only at low levels in adipocytes but was
highly expressed in the stromal vascular fraction (Figure 4B), similar to the liver where
GPR105 was only marginally expressed in hepatocytes, but highly expressed in the non-
parenchymal cells.
ATMs increase in obesity (17, 23), and a specific subpopulation of CD11c+, M1-like
macrophages has been shown to secrete pro-inflammatory cytokines that reduce insulin
sensitivity (17, 24). Although liver macrophages were reduced in number,
immunohistochemistry staining of epididymal adipose tissue with the macrophage marker
Mac2 did not show significant differences in crown-like structures in fat tissue (Figure 4C).
Likewise, flow cytometry did not show differences in either F4/80+CD11b+ (double
positive) macrophages (Figure 4D) or F4/80+CD11b+CD11c+ (triple positive) macrophages
(Figure 4E) in the eWAT stromal vascular fraction from GPR105 KO mice. We were also
unable to detect significant changes in pro-inflammatory gene expression. Although IL-1β
gene expression decreased, similar changes were not observed in TNFα and IL-6 gene
expression (Figure 4F).
GPR105 deletion reduces macrophage chemotaxis in vivo and in vitro
Since GPR105 depletion resulted in reduced macrophage numbers in liver, we next
investigated whether this phenomenon could be attributed to decreased macrophage
recruitment versus increased macrophage turnover. We therefore conducted an in vivo
monocyte tracking experiment to assess the ability of WT or GPR105 null monocytes to
migrate into liver and adipose tissues. We verified that the monocytes comprised over 90%
of WBC population after enrichment (Figure S1). PKH26-labeled monocytes isolated from
either GPR105 KO or WT donor mice were injected intravenously to WT recipient mice on
HFD. Five days after injection, PKH26-labeled cells in the non-parenchymal cell fraction
were counted by flow cytometry. We have previously shown that macrophages represent
>90% of the PKH-labeled cells recruited to the non-parenchymal fraction of both liver and
adipose tissue (25).
As shown in Figure 5A, fewer liver PKH26+ monocytes were identified in mice that
received GPR105 KO monocytes (Figure 5A). In contrast, the percentage of PKH26+ cells
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in the adipose stromal vascular fraction did not differ between the two groups (Figure 5B).
These results indicate that GPR105 plays a role in monocyte responsiveness to chemoattract
signals from liver, but not from adipose tissue. Moreover, the magnitude of decrease in liver
PKH26+ cells in GPR105 KO mice suggest that the decrease in liver F4/80+ cells (Figure
3G) likely reflects a difference in macrophage recruitment rather than resident tissue
macrophages (Kupffer cells) in HFD-fed GPR105 KO mice.
UDP-Glc acts as a potent endogenous agonist for GPR105 and is a substrate for glycogen
synthetase and protein glycosylation. Therefore we explored the potential role of UDP-Glc
as a chemoattractant released from liver tissues following HFD. To test whether UDP-Glc
could induce chemotaxis in a GPR105-mediated manner, we performed an in vitro
chemotaxis assay to determine whether increasing concentrations of UDP-Glc would induce
the migration of bone marrow derived macrophages derived from WT or GPR105 KO donor
mice. As shown in Figure 5C and D, we observed that 1mM UDP-Glc produced a 2.5-fold
increase in the migration of BMDMs from WT mice whereas this effect was abolished for
BMDMs from GPR105 KO mice.
Since UDP-Glc potentially represents an extracellular signaling molecule that could promote
the recruitment of macrophages in obese states, we next measured UDP-Glc levels in plasma
collected from mice fed either normal chow or HFD in order to determine whether UDP-Glc
levels increase in obesity. By employing HPLC analysis of nucleotide sugars, we discovered
that plasma UDP-Glc levels are significantly higher in obese mice (16.66 ± 3.42 nM in
HFD-fed vs. 4.70 ± 1.29 nM in standard chow-fed mice, p<0.005) (Figure 5E).
Improved insulin sensitivity following transplantation of GPR105-depleted bone marrow
To further investigate whether differences in macrophage recruitment could account for the
difference in insulin resistance phenotypes between whole-body GPR105 KO and WT mice,
we performed bone marrow transplantation (BMT) studies by injecting bone marrow cells
from either GPR105 KO (KO-BMT) or WT (WT-BMT) donors into irradiated WT
recipients. After reconstitution, GPR105 expression was barely detectable in circulating
white blood cells from KO BMT mice, showing nearly complete replacement of the bone
marrow with donor cells after transplant (Figure S2). We observed that KO-BMT mice
demonstrated a similar phenotype to the whole body knockout. As shown in Figure 6A,
glucose tolerance was similar between NC-fed KO-BMT and WT-BMT mice. However,
following a 12w HFD, KO-BMT mice exhibited a significant improvement in glucose
tolerance compared to diet-matched WT-BMT controls (Figure 6A).
This protection from HFD-induced insulin resistance in KO-BMT mice was further
supported by hyperinsulinemic-euglycemic clamp studies which showed that the glucose
infusion rate and insulin-stimulated glucose disposal rate were significantly higher in KO-
BMT mice than WT-BMT mice (Figure 6B and C). Insulin-stimulated suppression of
hepatic glucose output was somewhat enhanced in KO-BMT mice, although this difference
did not reach statistical significance (Figure 6D). Consistent with improved insulin
sensitivity, we found that insulin-stimulated AKT phosphorylation significantly increased in
liver, adipose and skeletal muscle of KO-BMT mice (Figure 6E).
DISCUSSION
Chronic tissue inflammation is now recognized as a key cause of systemic insulin resistance
in the context of obesity and Type 2 diabetes. A substantive literature has emerged
indicating that the accumulation of activated macrophages in tissues provides a mechanism
for inflammation-induced insulin resistance, since these cells secrete a variety of cytokines
which can directly impair insulin sensitivity in insulin target cells. Other immune cell types
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such as lymphocytes and eosinophils can also participate in these events, but their effects are
likely mediated by modulating macrophage chemotaxis and activation. Thus, the
macrophage would be the effector cell, causing decreased insulin sensitivity. Here, we report
the role of a macrophage-expressed GPCR termed GPR105, which, heretofore, has not been
implicated in obesity-associated chronic tissue inflammation and insulin resistance.
GPR105 (also known as the P2Y14 receptor) is a member of the P2Y purinergic receptor
subfamily. P2Y receptor subtypes have been identified in immune cells such as monocytes
and macrophages and exert effects on inflammatory signaling (26). For example, P2Y2
receptors regulate macrophage chemotaxis toward complement C5a in response to ATP
release via autocrine purinergic signaling (26). Unlike other P2Y receptors that are activated
by adenine and/or uracil nucleotides, GPR105 is a membrane receptor for UDP-glucose.
GPR105 expression has been reported in various human tissues, including the placenta,
adipose tissue, spleen, gut and discrete brain regions by microarray or quantitative PCR (6,
7). However, since immune cells are widely distributed among several tissue types, it was
previously unknown whether GPR105 is expressed by parenchymal or non-parenchymal
cells.
In this report, we demonstrate that GPR105 is highly expressed in the stromal vascular
fraction but not in the parenchymal fraction of liver and adipose tissue. Therefore, the tissue-
specific role of GPR105 requires careful interpretation since crosstalk between resident
immune and parenchymal cells within tissues and crosstalk with circulating leukocytes may
account for the in vivo phenotypes.
We show that GPR105 knockout mice are more insulin sensitive with reduced liver steatosis
and inflammation following HFD feeding. In addition, GPR105 mediates macrophage
chemotaxis to UDP-Glc in vitro and macrophage recruitment to liver tissues in response to
HFD in vivo. Notably, the most impressive phenotypic changes in HFD GPR105 KO mice
were observed in the liver. Hepatic insulin resistance in obesity is associated with increased
expression of inflammatory mediators and massive accumulation of intracellular lipid within
hepatocytes. Recruited hepatic macrophages (RHMs) and resident Kupffer cells are
important immune cell types in the liver and reside in the sinusoids where they are poised to
communicate with hepatocytes. Improved hepatic insulin sensitivity in HFD GPR105 KO
mice was associated with decreased recruited macrophage numbers, reduced tissue
inflammation, and reduced hepatic steatosis. Our monocyte tracking studies corroborated
these data, showing reduced migration of macrophages to the liver in HFD mice.
We also demonstrated that macrophage chemotaxis was mediated by GPR105 as BMDMs
obtained from GPR105 KO mice displayed significantly impaired migration towards a UDP-
Glc gradient in an in vitro transwell assay. GPR105 has been previously implicated in the
migration of immune cells. For example, GPR105 expressed in primitive hematopoietic cells
regulates the chemotaxis of these cells to conditioned media from the bone marrow stroma
(10). GPR105 expressed in endometrial tissues of the female reproductive tract also
facilitates the chemotaxis of neutrophils in response to UPDG (11). In our study, we
observed that fewer monocytes from GPR105 KO mice were recruited to the liver in
response to HFD in vivo.
Interestingly, increased hepatic UDP-Glc has been reported in association with the
development of obesity (27, 28). UDP-Glc has been shown to be a functional agonist for
GPR105 mediated cellular responses in various cell types (29–34), and the endoplasmic
reticulum and golgi apparatus provides the major route for extracellular release of UDP-Glc
(35). Furthermore, damaged cells may release nucleotides such as ATP and UDP-Glc during
inflammation and mechanical stress (11). Since HFD-induced lipotoxicity and inflammation
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have been shown to increase hepatocellular apoptosis and necrosis (36–38), we hypothesize
that UDP-Glc may act as an extracellular signaling molecule and chemoattractant for
macrophage recruitment via GPR105. In this study, we were able to demonstrate for the first
time that UDP-Glc levels in plasma are significantly higher in obese compared to lean mice.
Although further investigation is required to address this hypothesis, our results suggest that
UDP-Glc release from hepatocellular injury may trigger innate immune responses and
promote the development of hepatic insulin resistance.
In addition to improved hepatic insulin sensitivity, we observed improved global insulin
sensitivity in whole-body GPR105 KO mice, with enhanced insulin action not only in liver,
but also in skeletal muscle and adipose tissue. GPR105 is expressed at only very low levels
in murine muscle (7). Furthermore, we were unable to detect significant changes in
proinflammatory gene expression in adipose tissue. Prior studies have shown that strategies
that exclusively target insulin action in the liver can alter insulin sensitivity in extrahepatic
tissues (39, 40) by modifying circulating glucose. Thus, the improved insulin sensitivity in
muscle and fat of GPR105 KO mice could be secondary to indirect effects from the liver.
However, myeloid cells have been shown to be responsible for cross-talk involving
proinflammatory cytokines between insulin-responsive tissues (41). Since we observed
significantly improved insulin sensitivity in mice with a myeloid-specific GPR105 deletion
obtained by bone marrow transplantation, myeloid cells appear to play a primary role in
GPR105-mediated inflammation and insulin resistance in our study as well. Bone marrow
transplantation results in the reconstitution of several immune cell types in addition to
macrophages. Therefore, we cannot conclude that GPR105 in lymphocytes or other immune
cells does not contribute to our observed phenotype.
We have recently shown that recruited hepatic macrophages comprise over half of the
population of liver macrophages under HFD conditions (25). These cells are radio-sensitive
and turn over in a matter of weeks so that the RHMs in the KO BMT mice are essentially
donor-derived. On the other hand, the majority of resident Kupffer cells are radio-resistant
and turn over more slowly (42, 43) so they are probably not fully replaced at the time of our
studies (20 weeks after BMT). In contrast, the nearly all of the adipose tissue macrophages
are donor-derived after 8 weeks reconstitution and 12 weeks high fat feeding (Figure S3). To
the extent that chimerism of the Kupffer cells population exists at the time of our studies,
this would tend to underestimate the effect of GPR105 ablation on the hepatic phenotype,
consistent with the results of our clamp studies showing a smaller improvement in hepatic
glucose suppression in the KO BMT mice than that observed in the whole body GPR105
knockouts. Thus, our data overall suggest that GPR105-mediated macrophage recruitment to
the liver following HFD propagates strong inflammatory signals in the liver that may enter
the circulation to cause peripheral insulin resistance in other tissues such as muscle and fat.
In this study, we have expanded our understanding of GPR105 in vivo by demonstrating that
GPR105 null mice are protected from HFD-induced insulin resistance. This improvement in
systemic insulin sensitivity was accompanied by decreased macrophage infiltration and a
reduction in inflammation in the liver. We also showed that GPR105 mediates monocyte
migration to the liver in response to HFD, and that myeloid-specific deletion of GPR105
results in improved insulin sensitivity. Taken together, these data support the conclusion that
GPR105 participates in macrophage recruitment to the liver in chronic HFD feeding with
subsequent local inflammation and insulin resistance. Novel therapeutic strategies that
inhibit GPR105 and prevent macrophage migration may prove to be protective to the
development of insulin resistance and type 2 diabetes.
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Figure 1. Improved glucose homeostasis of GPR105 KO HFD-fed mice
(A) Body weight gain of WT and GPR105 KO mice on NC and HFD (n=12 per group).
(B) Food intake of WT and GPR105 KO mice on HFD (n=12).
(C) Glucose tolerance testing in NC and HFD mice. Glucose (1 g/kg) was injected
intraperitoneally after a 7h fast, and tail blood was collected for glucose measurement (n=8).
(D) Fasting insulin levels of WT and GPR105 KO mice on NC and HFD (n=8).
(E) Acute insulin secretion measured in HFD-fed WT and GPR105 KO mice at basal (7h
fast) and 15 min after oral glucose challenge (n=8).
(F) Insulin tolerance testing in HFD mice. Intraperitoneal insulin (0.6 U/kg) was injected to
7h-fasted HFD WT and GPR105 KO mice. Blood glucose was measured at the indicated
time points.
All values are expressed as means ± SEM. *p < 0.05 versus diet-matched WT.
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Figure 2. Improved insulin sensitivity of GPR105 KO HFD-fed mice
In vivo insulin sensitivity as determined by hyperinsulinemic-euglycemic clamp in WT
(n=6) and GPR105 KO (n=6) mice fed HFD. GIR (A), GDR (B), IS-GDR (C), basal and
clamp HGP (D), suppression of HGP (E), are presented as means ± SEM. *p < 0.05 versus
WT.
(F) Immunoblot analyses of Ser473 phosphorylation of Akt as well as total Akt and HSP90
in liver, adipose tissue and skeletal muscle. Tissues were collected before or at indicated
time after insulin injection (0.2 U/kg) into the inferior vena cava.
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Figure 3. Reduced macrophage infiltration and inflammation in liver
Liver weight (A), TG (B) and glycogen content (C) in liver are presented as means ± SEM.
*p < 0.05 versus WT (n=6–12 per group).
(D) Representative images of H&E-stained liver sections of HFD-fed WT and GPR105
mice. Scale bars represent 50 μm.
(E) GPR105 expression in hepatocytes and non-parenchymal cells by quantitative PCR.
Data are presented as means ± SEM. **p <0.005 (n=3). (F) Representative
immunohistochemistry images of liver sections stained with anti-F4/80 antibody. Scale bars
represent 50 μm.
(G) F4/80+ cell as a percentage of all non-parenchymal cells by flow cytometry. *p < 0.05
versus WT (n=4).
(H) Gene expression in liver measured by quantitative PCR. Data are presented as means ±
SD.
*p < 0.05 versus WT (n=8).
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Figure 4. Macrophages in adipose tissue
(A) eWAT weight as a percentage of total body weight (n=8).
(B) GPR105 expression in adipocytes and SVF cells by quantitative PCR.
(C) Representative immunohistochemistry images of eWAT stained with anti-Mac2
antibody. Scale bars represent 100μm.
(D) F4/80+CD11b+ and (E) F4/80+CD11b+CD11c+ cells in eWAT measured by flow
cytometry (n=6).
(F) Gene expression in eWAT.
Data are presented as means ± SD. *p < 0.05 versus WT (n=8).
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Figure 5. GPR105-mediated chemotaxis in vivo and in vitro
PKH26+ cells in liver non-parenchymal cells (A) and in eWAT SVF cells (B) of WT
recipient mice 5 days after injection of labeled monocytes from WT or GPR105 KO donors
(n=4). Data are presented as means ± SEM. *p < 0.05 versus WT.
(C–D) Chemotaxis of bone-marrow derived macrophages from WT or GPR105 KO mice
towards a UDP-glucose gradient in vitro (data from 3 independent experiments). *p < 0.05
versus WT.
(E) Measurement of UDP-Glc in plasma from mice fed either normal chow (NC) or HFD (n
= 8–10). **p <0.005.
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Figure 6. Improved glucose homeostasis and insulin sensitivity of GPR105 KO bone marrow
transplanted mice
(A) Glucose tolerance testing in BMT-WT and BMT-KO mice on NC or HFD (n=12). *p <
0.05 and **p < 0.005 versus diet-matched WT.
(B–D) Hyperinsulinemic-euglycemic clamp studies in BMT-WT (n=4) and BMT-KO (n=4)
mice fed with HFD. GIR (B), IS-GDR (C), suppression of HGP (D), are presented as means
± SEM. *p < 0.05 versus WT.
(E) Immunoblot analyses of Ser473 phosphorylation of Akt and HSP90 in liver, adipose
tissue and skeletal muscles of BMT-WT and BMT-KO. Tissues were collected at the
indicated times before and after insulin injection (0.2 U/kg). *p < 0.05 versus WT
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